早期淋巴结阴性乳腺癌保乳治疗与乳房切除术总生存比较
该匹配队列研究基于美国国家癌症数据库(NCDB)2006—2014年pT1-2、pN0、cM0乳腺癌患者,比较保乳治疗(BCT)与乳房切除术的总生存(OS),采用倾向评分逆概率加权匹配。BCT组5年OS为94.4%对91.8%,7年OS为90%对85.2%(均P<0.001),多变量分析HR 0.66(95%CI 0.64-0.69,P<0.001)。亚组分析提示BCT的OS获益在复发评分(RS)>25及年龄>50岁患者中更明显。
要点
- 早期淋巴结阴性乳腺癌中,BCT与乳房切除术相比与更高的OS相关。
- 匹配后5年OS 94.4%对91.8%,7年OS 90%对85.2%,均P<0.001。
- BCT的OS获益在高RS(>25)及年龄>50岁患者中更明显。
核心结论
- 在早期、淋巴结阴性乳腺癌女性中,BCT与乳房切除术相比与改善的OS相关。
- BCT的OS改善似乎在高RS和年龄>50岁患者中最为明显。
- 这些发现需要前瞻性验证。
研究设计与样本
- 匹配队列分析,数据来自美国国家癌症数据库(NCDB)。
- 纳入2006—2014年接受BCT或乳房切除术的pT1-2、pN0、cM0乳腺癌患者。
- 采用倾向评分逆概率治疗加权(IPTW)及稳定权重匹配所有可获得的基线特征。
- 共识别144,263例接受BCT和87,379例接受乳房切除术的合格患者。
主要发现
- IPTW匹配后,BCT组OS高于乳房切除术组:5年OS 94.4%对91.8%(P<0.001)。
- 7年OS为90%对85.2%(P<0.001)。
- 双稳健多变量分析显示BCT与改善OS相关(HR 0.66,95%CI 0.64-0.69,P<0.001)。
- 亚组分析中,BCT与RS>25患者改善OS相关,但与RS≤25患者无关。
- 按年龄分层,仅>50岁患者接受BCT与改善OS相关。
关键数值与推荐
- BCT组5年OS 94.4%,乳房切除术组91.8%(P<0.001)。
- BCT组7年OS 90%,乳房切除术组85.2%(P<0.001)。
- BCT与OS关联的HR 0.66(95%CI 0.64-0.69,P<0.001)。
- BCT的OS获益见于RS>25患者,未见见于RS≤25患者。
- BCT的OS获益仅见于年龄>50岁患者。
临床怎么用
- 对于早期、淋巴结阴性乳腺癌女性,BCT可作为与改善OS相关的治疗选择。
- 在高RS(>25)及年龄>50岁患者中,BCT的OS获益可能更明显。
- 上述关联需前瞻性验证后方可用于临床决策。
局限性
- 为回顾性匹配队列分析,存在未测量混杂的可能。
- 研究结论需前瞻性验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Recent retrospective studies suggest improved overall survival (OS) with breast conserving therapy (BCT), including breast conserving surgery and adjuvant whole breast radiotherapy, compared to mastectomy in the modern era. The patient subset most likely to benefit from BCT remains unclear, and the role of Oncotype DX Recurrence Score (RS) in this context is unknown. We compared BCT to mastectomy in early-stage, node-negative breast cancer. We further explored outcomes after stratification by RS and age. MATERIALS AND METHODS: We performed a matched-cohort analysis of National Cancer Database (NCDB) patients with pT1-2, pN0, cM0 breast cancer treated between 2006 and 2014 with BCT or mastectomy. Patients were matched for all available baseline characteristics using propensity scores with inverse probability of treatment weighting (IPTW) with stabilized weights. RESULTS: We identified 144,263 eligible patients treated with BCT and 87,379 patients treated with mastectomy. After IPTW-matching, OS was higher with BCT compared to mastectomy: 5-year OS of 94.4% vs. 91.8% (P < 0.001) and 7-year OS of 90% vs. 85.2% (P < 0.001). Doubly robust multivariable analysis showed an association between BCT and improved OS (HR 0.66, 95% CI, 0.64-0.69, P < 0.001). In a subset analysis, BCT was associated with improved OS in patients with RS >25, but not patients with RS ≤25. When stratified by age, only patients >50 years had improved OS with BCT. CONCLUSION: BCT is associated with improved OS compared to mastectomy in women with early-stage, node-negative breast cancer. The improvement in OS with BCT appears to be most pronounced in patients with high RS and >50 years of age. Prospective validation of these findings is required.
引用
- Almahariq MF, Quinn TJ, Siddiqui Z, et al. Breast conserving therapy is associated with improved overall survival compared to mastectomy in early-stage, lymph node-negative breast cancer. Radiother Oncol. 2019. PMID: 31615634. doi:10.1016/j.radonc.2019.09.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。